<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900038</url>
  </required_header>
  <id_info>
    <org_study_id>212483</org_study_id>
    <nct_id>NCT04900038</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults</brief_title>
  <acronym>DYNAMIC</acronym>
  <official_title>A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of GSK3640254 + DTG relative to&#xD;
      lamivudine (3TC) + DTG in treatment-naïve adult participants living with human&#xD;
      immunodeficiency virus (HIV)-1. The participants will be randomized to one of the three doses&#xD;
      of blinded GSK3640254 (100, 150, or 200 milligrams [mgs]) or a reference arm of blinded&#xD;
      3TC-each in combination with open label DTG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">June 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, parallel-group study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The dose level of GSK3640254 in each of the treatment arms containing GSK3640254 will be blinded to the research participants and all study personnel during the study through the Week 24 primary endpoint.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) of participants with plasma HIV-1 ribonucleic acid (RNA) less than(&lt;)50 copies per milliliter (c/mL) at Week 24 using the Food and Drug Administration (FDA) snapshot algorithm</measure>
    <time_frame>At Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with plasma HIV-1 RNA &lt;50 c/mL at Week 48 using the FDA snapshot algorithm</measure>
    <time_frame>At Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of HIV-1 RNA through Weeks 24 and 48</measure>
    <time_frame>Through Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HIV-1 RNA through Weeks 24 and 48</measure>
    <time_frame>Baseline (Day 1), through Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of cluster of differentiation 4+ (CD4+) T-cell counts through Weeks 24 and 48</measure>
    <time_frame>Through Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ T-cell counts through Weeks 24 and 48</measure>
    <time_frame>Baseline (Day 1), through Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting serious adverse events (SAEs), Deaths, adverse events leading to discontinuation (AELD) and adverse events of special interest (AESIs) through Weeks 24 and 48</measure>
    <time_frame>Through Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who develop genotypic resistance through Week 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who develop phenotypic resistance through Week 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough) of GSK3640254 at Weeks 2, 4, 8, 12, 24 and 48</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 24 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Blinded GSK3640254 100 mg + unblinded DTG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive blinded GSK3640254 100 mg + unblinded DTG through Week 24 (double blind phase). The participants will receive optimal dose of unblinded GSK3640254 + unblinded DTG from Week 24 to 52 (open label phase).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded GSK3640254 150 mg + unblinded DTG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive blinded GSK3640254 150 mg + unblinded DTG through Week 24 (double blind phase). The participants will receive optimal dose of unblinded GSK3640254 + unblinded DTG from Week 24 to 52 (open label phase).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded GSK3640254 200 mg + unblinded DTG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive blinded GSK3640254 200 mg + unblinded DTG through Week 24 (double blind phase). The participants will receive optimal dose of unblinded GSK3640254 + unblinded DTG from Week 24 to 52 (open label phase).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded 3TC 300 mg + unblinded DTG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive blinded 3TC 300 mg capsules + unblinded DTG through Week 24 (double blind phase). The participants will receive unblinded 3TC 300 mg tablets + unblinded DTG from Week 24 to 52 (open label phase).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3640254</intervention_name>
    <description>GSK3640254 will be available as 25 mg or 100 mg tablets to be administered orally</description>
    <arm_group_label>Blinded GSK3640254 100 mg + unblinded DTG</arm_group_label>
    <arm_group_label>Blinded GSK3640254 150 mg + unblinded DTG</arm_group_label>
    <arm_group_label>Blinded GSK3640254 200 mg + unblinded DTG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>DTG will be available as 50 mg tablets, to be administered orally</description>
    <arm_group_label>Blinded 3TC 300 mg + unblinded DTG</arm_group_label>
    <arm_group_label>Blinded GSK3640254 100 mg + unblinded DTG</arm_group_label>
    <arm_group_label>Blinded GSK3640254 150 mg + unblinded DTG</arm_group_label>
    <arm_group_label>Blinded GSK3640254 200 mg + unblinded DTG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine capsules</intervention_name>
    <description>3TC will be available as 300 mg capsules, to be administered orally as a blinded treatment</description>
    <arm_group_label>Blinded 3TC 300 mg + unblinded DTG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine tablets</intervention_name>
    <description>3TC will be available as 300 mg tablets, to be administered orally as an unblinded treatment</description>
    <arm_group_label>Blinded 3TC 300 mg + unblinded DTG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monotherapy)&#xD;
             received after a known diagnosis of HIV-1 infection.&#xD;
&#xD;
          -  Documented HIV infection and Screening plasma HIV-1 RNA greater than or equal to&#xD;
             (&gt;=)1000 c/mL.&#xD;
&#xD;
          -  Screening CD4+ T-cell count &gt;=300 cells per millimeter^3 (cells/cubic millimeter).&#xD;
&#xD;
          -  Body weight &gt;=50.0 kilograms (kg) (110 pounds [lbs.]) for men and &gt;=45.0 kg (99 lbs.)&#xD;
             for women and body mass index (BMI) &gt;18.5 kilograms per meter^2 (kg/meter square).&#xD;
             Calculations will utilize sex assigned at birth.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3&#xD;
             disease [CDC, 2014], except cutaneous Kaposi's sarcoma not requiring systemic therapy.&#xD;
&#xD;
          -  Presence of primary HIV infection, evidenced by acute retroviral syndrome (example&#xD;
             [e.g.], fever, malaise, fatigue, etc.) and/or evidence of recent (within 3 months)&#xD;
             documented viremia without antibody production and/or evidence of recent (within 3&#xD;
             months) documented seroconversion.&#xD;
&#xD;
          -  Unstable liver disease (as defined by any of the following: presence of ascites,&#xD;
             encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or&#xD;
             persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of&#xD;
             Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver&#xD;
             disease per investigator assessment);&#xD;
&#xD;
          -  History of ongoing or clinically relevant hepatitis within the previous 6 months.&#xD;
&#xD;
          -  Any history of significant underlying psychiatric disorder.&#xD;
&#xD;
          -  Any history of major depressive disorder with or without suicidal features, or anxiety&#xD;
             disorders, that required medical intervention (pharmacologic or not) such as&#xD;
             hospitalization or other inpatient treatment and/or chronic (&gt;6 months) outpatient&#xD;
             treatment.&#xD;
&#xD;
          -  A pre-existing condition, in the opinion of the Investigator or Medical Monitor, that&#xD;
             could interfere with normal gastrointestinal anatomy or motility (e.g.,&#xD;
             gastroesophageal reflux disease [GERD], gastric ulcers, gastritis, inflammatory bowel&#xD;
             disease), hepatic and/or renal function, or with the absorption, metabolism, and/or&#xD;
             excretion of the study interventions or render the participant unable to take oral&#xD;
             study treatment.&#xD;
&#xD;
          -  Familial or personal history of long QT syndrome or sudden cardiac death.&#xD;
&#xD;
          -  Active treatment for a viral infection other than HIV-1, such as Hepatitis B, with an&#xD;
             agent that is active against HIV-1 (were known to be infected with HIV-1 after&#xD;
             treatment for Hepatitis B was completed).&#xD;
&#xD;
          -  Participants who require concomitant medications known to be associated with a&#xD;
             prolonged corrected QT (QTc) interval.&#xD;
&#xD;
          -  Exposure to an experimental drug, human blood product, monoclonal antibody, or vaccine&#xD;
             (which does not have emergency, conditional, or standard market authorization) within&#xD;
             28 days prior to the first dose of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Franco Antoni Felizarta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tulika N Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cindy S Firnhaber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Moti N Ramgopal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael B. Wohlfeiler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Harold Katner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Debbie P. Hagins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Blair Thedinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Conway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lizette Santiago-Colón</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Morales-Ramirez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Del Mar Masia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sant Boi de Llobregat</city>
        <zip>08830</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vicens Díaz de Brito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human immunodeficiency virus-1</keyword>
  <keyword>GSK3640254</keyword>
  <keyword>Dolutegravir</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

